A First-in-human, Phase 1/2, Multicenter, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of ADCE-D01, a Humanized Anti-human UPARAP Antibody Linked to a Topoisomerase I Inhibitor, in Patients with Metastatic And/or Unresectable Soft Tissue Sarcoma
Latest Information Update: 08 May 2025
At a glance
- Drugs ADCE D01 (Primary)
- Indications Soft tissue sarcoma
- Focus Adverse reactions; First in man
- Acronyms ADCElerate-01
- Sponsors ADCendo
Most Recent Events
- 08 May 2025 Last checked against ClinicalTrials.gov: US National Institutes of Health
- 29 Apr 2025 Status changed from not yet recruiting to recruiting.
- 14 Oct 2024 New trial record